Physician profile
Barry Fuller
NPI 1134182645
$2,045.53
in general payments reported to CMS, 2019-2025
30 companies · $395 in 2025
The $395 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $82.29 · 2021: $239 · 2022: $363 · 2023: $130 · 2024: $510 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,033.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $321.93 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $187.17 | 2019-2025 | Cequa |
| Rxsight INC | $179.75 | 2022-2024 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Allergan, INC. | $153.75 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $105.60 | 2023-2024 | Xiidra, Miebo, Envista Mx60 Iol |
| Astellas Pharma US INC | $97.09 | 2024 | Izervay |
| Dompe US, INC. | $76.72 | 2022-2024 | Oxervate |
| Abbvie INC. | $76.05 | 2022-2025 | |
| Horizon Therapeutics Plc | $74.32 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $73.54 | 2019-2023 | Tecnis Iol, Healon Duet Pro |
| Alcon Vision LLC | $73.38 | 2019-2025 | Hydrus Microstent |
| Biotissue Holdings INC. | $73.00 | 2021-2025 | |
| Oyster Point Pharma, INC. | $69.96 | 2022-2024 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $66.84 | 2019-2021 | |
| Thea Pharma INC. | $60.69 | 2022-2024 | Iyuzeh |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $53.69 | 2019 | |
| Apellis Pharmaceuticals, INC. | $34.93 | 2025 | |
| Aerie Pharmaceuticals, INC. | $33.29 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $28.33 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $28.14 | 2021-2022 | |
| Ocular Therapeutix, INC. | $27.03 | 2019-2021 | |
| Amgen INC. | $24.37 | 2024 | Tepezza |
| Akorn Operating Company LLC | $17.92 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $17.89 | 2024 | Forum |
| Omeros Corporation | $16.64 | 2020 | |
| Akorn, INC. | $16.24 | 2019 | |
| New World Medical,INC. | $16.12 | 2022 | |
| Sight Sciences, INC. | $15.12 | 2021 | |
| Eyepoint US, INC. | $13.06 | 2019 | |
| Glaukos Corporation | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.